Committee composition is a recurrent theme within the literature on Institutional Animal Care and Use Committees (IACUCs). The ability of IACUCs to ensure the ethical treatment of nonhuman research subjects depends upon who makes up these committees. Non-scientists and those not affiliated with the research institution have been deemed indispensable for the democratic, objective review of protocols and, thus, for ethical treatment. IACUCs’ critics and partners alike have persistently offered suggestions for how to further optimize committee composition towards these ends. (...) This paper contributes to the ongoing conversation by advocating for the addition of holistic species experts to IACUCs, arguing that holistic species experts are as indispensable for the political and epistemic viability of protocol reviews as non-scientists and non-affiliates. Holistic species experts are defined here as members of the larger community who have extensive firsthand experience with animals living and dying under relatively ideal conditions. If we accept that non-scientists and non-affiliates are crucial for IACUCs' ethical treatment of animals, then we have every reason to embrace holistic species experts. The values, welfare expertise, and productive epistemic dissonance that these experts bring to the table would prove invaluable. (shrink)

Pharmaceutical firms seek to fulfill their responsibilities to stakeholders by developing drugs that treat diseases. We evaluate the social and financial costs of developing new drugs relative to the realized benefits and find the industry falls short of its potential. This is primarily due to legislation-mandated reliance on animal test results in early stages of the drug development process, leading to a mere 10 percent success rate for new drugs entering human clinical trials. We cite hundreds of biomedical studies from (...) journals including Nature, Science, and the Journal of the American Medical Association to show animal modeling is ineffective, misleading to scientists, unable to prevent the development of dangerous drugs, and prone to prevent the development of useful drugs. Legislation still requires animal testing prior to human testing even though the pharmaceutical sector has better options that were unavailable when animal modeling was first mandated. We propose that the U.S. Food and Drug Administration and Congress should work together to abolish regulations and policies that require animal use. Doing so will benefit pharmaceutical industry stakeholders, including patients whose health depends on drugs and the many people who rely on the financial well-being of pharmaceutical firms. (shrink)

Dear Editor,The April 2014 issue of Theoretical Medicine and Bioethics [1] presented eight essays regarding the use of nonhuman animals in biomedical research. While I appreciate the essays concerning contemporary research—which were well written and offered new thinking from the fields of ethics and ethology—I believe the journal, via the topics and the authors chosen, failed to communicate the most important fact regarding the current science pertinent to the use of nonhuman animals in research.The foundational reason for using chimpanzees and (...) other animals in research is their predictive value for human response to drugs and disease. This was alluded to by several of the authors when they discussed the necessity of using nonhuman animals. For example, Smith writes: “A common assumption in the selection of nonhuman animal subjects for research and the approval of research is that, if the risks of a procedure are too great for humans, and if there is a so-called scientific necessity, .. (shrink)